Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 92,052 |
|
|||||
| News | - | ||||||
| Day High | 7.46 | Low High |
|||||
| Day Low | 7.116 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TScan Therapeutics Inc | TCRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 0.41% | 7.32 | 16:02:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.34 | 7.116 | 7.46 | 7.32 | 7.29 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,262 | 92,052 | $ 7.32 | $ 673,860 | - | 1.62 - 9.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:05 | formt | 550 | $ 7.32 | USD |
TScan Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 349.54M | 47.88M | - | 21.05M | -89.22M | -1.86 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TScan Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TCRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.82 | 7.55 | 6.71 | 7.11 | 171,697 | 0.50 | 7.33% |
| 1 Month | 8.03 | 8.155 | 6.58 | 7.07 | 221,382 | -0.71 | -8.84% |
| 3 Months | 5.13 | 9.00 | 4.9642 | 7.09 | 208,069 | 2.19 | 42.69% |
| 6 Months | 3.43 | 9.00 | 3.15 | 6.37 | 168,120 | 3.89 | 113.41% |
| 1 Year | 2.40 | 9.00 | 1.62 | 4.09 | 493,266 | 4.92 | 205.00% |
| 3 Years | 12.00 | 14.71 | 1.45 | 4.12 | 222,354 | -4.68 | -39.00% |
| 5 Years | 12.00 | 14.71 | 1.45 | 4.12 | 222,354 | -4.68 | -39.00% |
TScan Therapeutics Description
| TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
